Program
direclidine
Also written as “NBI-1117568”, “HTL0016878” and “HTL0016878.HCl Solution 10 mg”.
Its studies are mostly in Schizophrenia · Mania, led by 2 companies.
Drug pageDireclidine: every studyAll 8 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Neurocrine Biosciencesits history only | 65 open or running | phase 3since Apr 30, 2025 | Sep 14, 2022 | Oct 2027phase 3 · NCT06963034 |
| Nxera Pharma UK | 30 open or running | phase 1since Aug 3, 2017 | Aug 3, 2017 | none ahead |
Also a collaborator on its studies: AbbVie.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Nxera Pharma UK only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Aug 3, 2017First study: phase 1 study in HealthyFirst studyNCT03244228 · 120 enrolled · United Kingdom
- Apr 15, 2021Phase 1 study in Healthy SubjectsNCT04849286 · 16 enrolled · United Kingdom
- Jun 21, 2021Phase 1 study in Healthy SubjectsNCT04935320 · 15 enrolled · United Kingdom
- Aug 11, 2024Named direclidineINNProposed as its International Nonproprietary Name in WHO's List 131 · before, NBI-1117568, HTL0016878
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 Nxera Pharma UK leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04935320Healthy Subjects · United Kingdom | 1 | Completed | Oct 29, 2021 | 15 |
| NCT04849286Healthy Subjects · United Kingdom | 1 | Completed | Dec 7, 2018 | 16 |
| NCT03244228Healthy · United Kingdom | 1 | Completed | Sep 23, 2019 | 120 |
How it is read
Names in the registry
- “NBI-1117568”, 6 entries
- “HTL0016878”, 2 entries
- “HTL0016878.HCl Solution 10 mg”, 1 entry
- “HTL0016878.Citrate Capsule 10 mg”, 1 entry
Codes read as this program: HTL0016878.
Conditions, from the studies’ own filings
- Schizophrenia, 5 studies
- Mania, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.